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Role of hyperglycemia and insulin resistance in determining sodium
retention in non-insulin-dependent diabetes. Sodium retention has been
advocated to give rise to hypertension in humans. Increases in blood
glucose and insulin concentrations ensue in the stimulation of sodium
reabsorption by the kidney. Although the combined occurrence of
hyperglycemia and hyperinsulinemia, frequently secondary to insulin
resistance with regard to carbohydrate metabolism, is a hallmark of
non-insulin dependent diabetes (NIDDM), the role of these abnormal-
ities in determining an impaired natriuresis in NLDDM is not yet fully
understood. We studied sodium homeostasis in 14 control subjects and
59 NIDDM normotensive, normoalbuminuric patients who were di-
vided into two groups with markedly impaired (Group 2 NIDDM: 30)
and less severely impaired (Group 1 NIDDM: 29) insulin sensitivity
during euglycemic-hyperinsulinemic (80 to 90 U/ml plasma insulin)
clamp. A hyperglycemic (9 mmol/liter plasma glucose)—nearly euinsu-
linemic (20 to 40 U/ml plasma insulin) clamp was also performed in the
same 14 controls and in two cohorts of 22 Group 2 and 17 Group 1
NIDDM patients. The two groups of patients had similar overnight
fasting glucose levels (Group 1 NIDDM vs. Group 2 NIDDM: 176 13
vs. 185 15 mg/dl, mean SE). Conversely, overnight fasting plasma
insulin was significantly higher in Group 2 NIDDM than in Group I
NIDDM patients (Group 1 NIDDM vs. Group 2 NIDDM: 12 3 vs. 18
3 U/ml, P < 0.05). Both NIDDM Groups had higher plasma glucose
and insulin than controls (75 4 mg/dl and 6 3 U/ml). Blood
pressure levels and albumin excretion rates were slightly but signifi-
cantly higher in Group 2 NIDDM, but not in Group I NIDDM patients,
than in controls. Insulin administration during the euglycemic-hyperin-
sulinemic clamp decreased in a similar manner the sodium excretion
rate in controls and in both NIDDM groups. Conversely, the sodium
excretion rate was always significantly lower in Group 2 than in Group
I NIDDM patients and in controls during the hyperglycemic, near
euinsulinemic clamp (euglycemia and hyperglycemia; Controls vs.
Grouplvs.Group2:156±l4andl23±l5vs.138±l7andlll±lO,
NS; vs. 101 8 and 74 9, P < 0.01 vs. both, tmol min 1.73
m2). The sodium excretion rate was lower during hyperglycemia than
euglycemia both in controls and NIDDM patients. An inverse relation-
ship was observed between daily sodium excretion rate and glucose
filtered load in both Group 1 and Group 2 NIDDM patients, at least up
to a glucose filtered load of 220mg min 1.73 m2. The daily sodium
excretion rate was significantly lower in Group 2 than in Group 1
NIDDM patients, despite similar circulating glucose levels and rates of
glucose filtered load. We conclude that excessive, glucose-bound, renal
sodium reabsorption occurs in all normotensive, normoalbuminuric
NIDDM patients, but that sodium retention is markedly increased in
patients with severe insulin resistance, despite similar circulating levels
of glucose and insulin.
Sodium retention has been claimed to play a major role in the
pathogenesis of arterial hypertension [1]. Furthermore hyper-
tension is often associated with hyperinsulinemia in obese [2, 3]
and non-obese [4] subjects and in non-insulin-dependent diabe-
tes (NIDDM) [5]. Since insulin stimulates sodium reabsorption
at renal level [6], it can be postulated that the sodium retaining
action of insulin is the pathogenetic link between hyperinsulin-
emia and hypertension.
Sodium retention is associated with hypertension and hyper-
insulinemia in NIDDM [5]. In NIDDM hyperinsulinemia is
frequently secondary to impaired insulin sensitivity, which
causes hyperglycemia, which in turn stimulates insulin secre-
tion [5]. On the other hand one cannot rule out the hypothesis
that sodium retention and hypertension are linked to an under-
lying defect identified by insulin resistance itself rather than by
hyperinsulinemia, which can be seen only as an ancillary event
[7—9]. It is not yet clearly established whether NIDDM patients
are insulin resistant with respect to carbohydrate metabolism or
to renal sodium handling. SkØtt et al [101 recently reported that
the sodium retaining effect of insulin is preserved in NIDDM
with peripheral insulin resistance during acute insulin adminis-
tration. An alternative hypothesis to explain sodium retention
in NIDDM could be that hyperglycemia results in a high glucose
filtered load at the renal level, which in turn increases renal,
glucose-induced sodium reabsorption [11, 13]. According to this
view hyperglycemia, rather than hypennsulinemia secondary to
peripheral insulin resistance, is the responsible mechanism for
sodium retention in NIDDM.
The aim of the present study was to investigate the patho-
genesis of sodium retention in NIDDM. More particularly, we
studied sodium homeostasis in two groups of NIDDM patients
characterized by similar circulating glucose levels and different
patterns of insulin sensitivity.
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Methods
Subjects
Fifty-nine consecutive patients with NIDDM, normal blood
pressure levels and normal albumin excretion rate, attending
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Controls
Group 1
NIDDM
Group 2
NIDDM
Men/women 8/6 14/15 16/14
Age years 49 2 51 4 51 3
Body mass index kg m
Systolic blood pressure mm Hg
28 2
130 4
29 4
132 4
29 3
136
Diastolic blood pressure mm Hg 77 3 78 3 82 3
Diabetes duration years
Sulphonilurea treatment %
Albumin excretion rate jsg/min
—
—
4 2
7 2
49 67 4
8 3
55 6b
16 4a,b
Glycated hemoglobin Alc% 4.9 0.3 7.9 0.6a 8.1 o.9
Glucose excretion g/day 0 0 4.5 0.9a 5.1 1.2
the outpatient's clinic of the Internal Medicine Department at
the University of Padova between 1983 and 1992, gave their
informed consent to the study, which was approved by the
Ethical Committee of the Faculty of Medicine. NIDDM was
diagnosed when fasting plasma glucose was higher than or equal
to 7.8 mmol per liter on two different occasions [14]. The
patients were older than 35 years. No patient was on insulin
therapy; about half of the patients were on suiphonilurea
treatment (Table 1). No patient had postural hypotension,
tachycardia or other clinical symptoms of autonomic neuropa-
thy. Two out of thirty and one out of twenty-nine patients from
Groups 2 and 1 NIDDM patients, respectively, had an abnormal
Valsalva maneuver. One patient in Group 2 and one in Group 1
NIDDM had abnormal hand grip and lying-to-standing maneu-
vers. Fourteen non-diabetic subjects matched for sex, age and
body weight, who had a negative family history for diabetes,
served as controls (Table 1). Patients were allocated to two
groups on the basis of the rate of whole body glucose utiliza-
tion rate during a euglycemic insulin clamp, with 40
mU. rn2. min insulin infusion for 150 minutes [15]. Whole
body glucose utilization was used as an index, chiefly reflecting
extrahepatic insulin action, whereas hepatic glucose output was
used as an index of hepatic insulin action [15]. Thirty patients
(Group 2 NIDDM) had whole body glucose utilization rates
lower than the nadir value in the controls (Fig. 1), whereas
twenty-nine patients had whole body glucose utilization rates
within the range of the controls. Particular attention was paid to
have a group of controls with a body mass index similar to that
of NIDDM patients, to overcome the bias that possible differ-
ences in sodium homeostasis were due to differences in body
weight (Table 1). Blood pressure levels were below 145 over 90
mm Hg both in controls and NIDDM patients on at least three
occasions as measured with a Hawksley random zero sphyg-
mornanorneter with two different cuff sizes (12 x 35 and 12 x 45
mm for body mass index lower and higher than 27 kg/rn2,
respectively; Hawksley and Sons, Lancing, UK), in agreement
with the statement of the Working Group on Hypertension in
Diabetes [16]. Three 24-hour urine collections were performed
in the last six months preceding the admission into the ward to
measure albumin excretion rate. NIDDM patients with an
albumin excretion rate above 30 jig/mm in the three urine
collections did not participate in the present study. When
admitted into the ward, patients and controls followed an
Table 1. Clinical features in the six months preceding admission into
the ward of 14 Control subjects and of 59 NIDDM patients with
markedly impaired (Group 2 NIDDM) or less severely impaired
(Group 1 NIDDM) insulin sensitivity
P<0.05
P<0.01
.
.
Data are mean SE.
a P < 0.05 NIDDM vs. Controls
b P < 0.05 NIDDM2 vs. NIDDMI
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Fig. 1. Individual and mean insulin-mediated whole body glucose
utilization rate in 59 norm otensive, normoalbuminurjc non-insulin-
dependent diabetic (NIDDM) patients (right bar) and in 14 age- and
weight-matched control subjects (left bar) during the euglycemic,
hyperinsulinemic (40 mU m2 ,nin') clamp. Symbols are: (A)
NIDDM patients with whole body glucose utilization closer to the
normal range (Group I NIDDM, N = 29); (0) those with whole body
glucose utilization below (Group 2 NIDDM) the nadir value in controls.
P < 0.05, NIDDM Group I vs. Controls; P < 0.01, NIDDM Group 2 vs.
Controls.
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isocaloric diet containing 55% carbohydrate, 25% fat, and 20%
protein and 125 mmol . day' 1.73 m2 sodium chloride for at
least eight days before each test.
Euglycemic-hyperinsulinemic clamp
Insulin sensitivity was assessed by insulin clamp technique as
previously described by our group [15]. Fourteen control and
fifty-nine NIDDM subjects were studied for 120 minutes at the
plasma glucose level shown by each subject at baseline after an
overnight fast (Baseline Step). Euglycemia was then achieved
and maintained in NIDDM patients and maintained in controls
by a 20 mU . m2• min insulin infusion for 180 minutes. The
rate of continuous insulin infusion was 40 mU . m2 min' for
a further 150 minutes, during which plasma glucose concentra-
tion was held constant at euglycemic values by variable infu-
sions of exogenous glucose (20% wt/vol). Whole body glucose
disposal was assessed by isotope dilution technique, employing
[6.62H2] glucose (98.6% 2H2; Tracer Technologies, Cambridge,
Massachusetts, USA). The tracer was administered as a primed
constant infusion for two hours before the start of the insulin-
clamp period, and was continued throughout the experimental
period. Tracer administration was adjusted continuously to
clamp the circulating value of tracer glucose enrichment ac-
cording to the "Hot Glucose Infusion Technique" by Doria et
al [15] and Finegood et al [17]. Rates of glucose turnover in the
systemic circulation were calculated from the isotopic data by
using a two-compartment model for non-steady-state glucose
kinetics, after correction for changes in glucose levels in a
distribution volume of 250 ml per kilogram as described in detail
[15].
Hyperglycemic and euglycemic-nearnormo-insulinemic clamp
To further clarify the role of hyperglycemia and hyperinsu-
linemia in sodium metabolism, twenty-nine out the fifty-nine
overall NIDDM patients and fourteen controls were studied
after an overnight, constant subcutaneous infusion of insulin
(Actrapid HM, Novo, Rome, Italy) using a bolus MC 20 insulin
infusion device (Miles Ames, Cavenago, Milan, Italy) to
achieve and maintain euglycemia. Different rates of insulin
infusion were used in NIDDM patients and controls to achieve
similar circulating hormone concentrations (Group 2 vs. Group
I vs. Controls: 1.0 0.2 vs. 1,4 0.3 vs. 2.0 0.4
U . hr 1.73 m2). After the overnight fast the constant
insulin infusion was continued for 240 minutes, and the patients
were connected to an artificial pancreas (Biostator Miles Ames,
Milan, Italy) to maintain a blood glucose concentration at 4.5
mmollliter by means of constant saline infusion (0.2 mi/mm to
maintain patency of catheters) and variable glucose infusion
(10% wt/vol glucose 58, 49 and 59 ml/240 mm in Controls,
Group 1 and 2 NIDDM patients, respectively) [18]. Insulin
infusion was further continued for 240 minutes to clamp the
blood glucose concentration at 9.0 mmol/liter (10% wt/vol
glucose 138, 152 and 149 ml/240 mm, respectively). Five mmol
of KC1 per hour were administered throughout to avoid changes
in circulating potassium concentrations. No labeled glucose
was administered.
Urine was collected every 60 minutes in all patients, in the
first 240 minutes during euglycemia, and in the last 240 minutes
during hyperglycemia to measure sodium excretion rate (SER).
Blood samples were drawn every 15 minutes to measure sodium
potassium, glucose and insulin concentrations. Patients drank
one liter of tap water before commencing and 0.3 liter every 30
minutes thereafter until the end of insulin infusion so that urines
could be collected without need of bladder catheterization.
Renal function measurements
After a 12-hour overnight fast, all patients and control sub-
jects received one Venflo cannula (1.1 mm O.D.), into an
antecubital vein for the primed intravenous infusion of the
tracer (1 Ci min' 1.73 m2 of 51Cr-EDTA, Amersham,
Buckinghamshire, UK). A second cannula (1.1 mm O.D.) was
inserted into an antecubital vein of the controlateral arm for 210
minutes. The cannula was filled with 0.5 to 0.7 ml of isotonic
saline, and the first 1 ml of blood sample was subsequently
discarded at each sample time. At 8:00 a.m. a 30 ml blood
sample was taken for routine biochemical parameters. A base-
line sample was collected just before tracer injection for back-
ground radioactivity measurement. Then patients voided and
urines were discarded. The glomerular filtration rate (GFR) was
evaluated as described in detail elsewhere [18], using three
30-minute clearance periods from the 120th to the 210th minute
of constant tracer infusion. Twenty-four-hour urine collection
during the same day was used to measure daily sodium excre-
tion rate (Natr). Throughout this period, three fasting and three
postprandial blood samples were collected to measure plasma
glucose. The average value of these six plasma glucose mea-
surements was used to calculate glucose filtered load (GFL),
that is, plasma glucose concentration multiplied by GFR.
Analytical methods
Biochemical parameters were measured by standard methods
[19]. Glycated hemoglobin A1 was measured by high pressure
liquid chromatography [20], and plasma and urine glucose by
enzymatic [21] techniques. Plasma insulin concentration was
measured by radioimmunoassay technique [221. Plasma C pep-
tide levels were determined by radioimmunoassay technique
[23] at baseline and after five minutes of glucagon (1 mg;
Glucagon Novo, Bagsvaerd, Denmark) intravenous injection.
Stimulated C peptide concentration was higher than 3.0 nmol/
liter in all NIDDM patients. Albumin concentration in the
24-hour urine specimen was measured by radioimmunoassay
technique [24]. Albumin and glucose daily excretion rates were
measured every two months in the six months preceding the
admission into the ward, and were expressed as average value
of these three determinations.
Relationship between natriuresis and glucose filtered load
The raw data scattergram of natriuresis (Natr) versus glucose
filtered load (GFL) revealed a biphasic behavior characterized
by an initial decrease of Natr with augmenting GFL, followed
by a reverse increasing pattern when GFL levels exceeded
some threshold. A simple linear regression for describing the
relationship between Natr and GFL proved to be unsatisfactory
in terms of goodness of fit (r2 = 0.593 in Group 1, r2 = 0.384 in
Group 2), and an individual description of the two phases
appeared necessary. To find the best description of the data in
terms of mathematical/statistical adequacy and physiological
plausibility, various possible competing models were examined.
The following mathematical representation was accepted as the
most adequate:
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Table 2. Baseline overnight fasting biochemical data in 14 controls,
and in NIDDM patients with markedly impaired (Group 2 NIDDM)
and less severely impaired (Group 1 NIDDM) insulin sensitivity
Controls
Group I
NIDDM
(N = 29)
Group 2
NIDDM
(N = 30)
Plasma glucose mg/dl
Plasma insulin aU/ml
75 46 3 176 1312 3 185 1518 3a,b
Plasma sodium mmol/liter 139 2 139 2 140 3
Plasma potassium mmol/liter 4.0 0.2 3.9 0.3 3.9 0.2
Glomerular filtration rate 106 8 110 17 115 13
ml. mi,r' 1.73 m2
Data are mean SE.
a P < 0.05 NIDDM vs. controls
b P < 0.05 NIDDM1 vs. NIDDM2
N — f Natro — k1 (GFL — GFL0) for GFL  GFLsatatr —
1Natrsat + k2 (GFL — GFLsat) for GFL > GFLsat
where: GFL0 is the normal reference GFL, which was mea-
sured in the control group and averaged 93 mg. mm 1.73 m2;
Natr0 is the value of Natr corresponding to GFL0; k1 is the
slope of the initial decreasing phase; GFLsat is the threshold
value beyond which Natr increases; Natrsat is the value of Natr
corresponding to GFLsat; and k2 is the slope of the final
increasing phase.
The equivalent mathematical expression used for parameter
estimation is:
Natr = Natr0 — k1 (GFL — GFL0) +
(k2 — k1) max (0, GFL — GFLsa1),
where expression: max (0, GFL — GFLsat) = 0 if GFL
GFLsat or equals GFL — GFLsat if GFL> GFLsat. Natr and
GFL are the measured variables, GFL0 is a measured constant,
and Natr0, k1, k2, and GFLsat are parameters estimable by
nonlinear least squares [25].
Improvement of goodness of fit obtained by means of this
mathematical formulation (r2 = 0.784 in Group 1, r = 0.626 in
Group 2) was assessed by comparison with the simple linear
regression using the statistical F-test [26] (P = 0.0004 in Group
1, P = 0.0015 in Group 2).
Statistical methods
Differences among groups were tested by analysis of vari-
ance. If a statistically significant difference was found, differ-
ences between individual groups were tested by Student's (-test
with Bonferroni modification. Linear regression analysis and
multiple-step regression analysis were used to assess the influ-
ence on one dependent variable of one or several independent
variables. Differences in percentages were assessed by chi-
square analysis [251. Differences among fitting curves describ-
ing the relationship between Natr and GFL were tested by
chi-square analysis on the basis of confidence limits of pre-
dicted Natr for each value of GFL in the range from 50 to 350
mg/mm.
Results are expressed as mean SE unless otherwise desig-
nated.
Table 3. Biochemical data during the euglycemic hyperinsulinemic
(40 mU . m2 min insulin infusion rate) clamp in Controls and in
NIDDM patients with markedly impaired (Group 2 NIDDM) or less
severely impaired (Group 1 NIDDM) insulin sensitivity
Controls
Group 1
NIDDM
(N = 29)
Group 2
NIDDM
(N = 30)
Plasma insulin p.U/ml 88 5 88 7 91 7
CV% 6±2 7±2 6±3
Plasma glucose mg/dl 82 3 83 4 84 4
CV% 5±2 5±3 5±2
Plasma sodium concentration 139 4 141 4 140 3
mmollliter
Plasma potassium concentration 3.9 0.3 3.9 0.3 3.9 0.3
mmol/liter
Data are mean SE. CV is coefficient of variation.
Results
The glycated hemoglobin A1 levels and the rates of daily
glucose excretion were similarly higher in Group 1 and 2
NIDDM patients than in Controls in the six months preceding
the admission into the ward (Table 1).
The mean fasting plasma glucose concentration was signifi-
cantly higher in Group 1 and 2 NIDDM patients than in
Controls. The mean arterial insulin concentration while fasting
was significantly higher in Group 1 and 2 NIDDM patients than
in Controls (Table 2). Group 2 NIDDM patients had higher
insulin levels than Group 1 NIDDM patients (Table 2). The
glomerular filtration rate was slightly, albeit not significantly,
higher in Group I and 2 NIDDM patients than in Controls
(Table 2). Albumin excretion rate was, on average, higher in
Group 2 than in Group 1 and Controls (Table 1). Systolic and
diastolic blood pressure levels were significantly higher in
Group 2 than in Group 1 NIDDM patients and Controls (Table
1). Diastolic blood pressure levels were 4 and 5 mm Hg higher
in Group 2 than in Group 1 and Controls, respectively, although
a degree of statistical significance was achieved only with
respect to the difference between Group 2 NIDDM patients and
Controls (Table 1). The mean arterial plasma glucose and
insulin concentrations during the euglycemic insulin-glucose
clamp period in 14 Controls and 59 Group 1 and 2 NIDDM
patients are shown in Table 3. Steady-state insulin levels were
similar in NIDDM patients and Controls. Arterial plasma so-
dium and potassium concentration remained stable at baseline
levels both in NIDDM patients and in Controls during the
euglycemic-insulin clamp (Table 3). Whole body glucose utili-
zation was by selection criteria higher in Controls than in Group
2 NIDDM patients. Also, Group 1 NIDDM patients had slightly
lower whole body glucose utilization rates than Controls (P <
0.05; Controls vs. Group I NIDDM vs. Group 2 NIDDM: 527
101 vs. 466 76, P <0.05, vs. 271 54mg. min . 1.73 m2,
P < 0.01; mean s; Fig. 1). Whole body glucose utilization
was lower in Group 2 than in Group 1 NIDDM patients (Fig. 1).
Sodium excretion and sodium clearance rates were significantly
decreased by insulin administration during the euglycemic
clamp. The shape of the decline in sodium clearance rate during
insulin infusion was similar in Group 1 and 2 NIDDM patients
and in Controls (Fig. 2). No significant changes were observed
with regard to systolic and diastolic blood pressure levels
Nosadinj et al: Insulin sensitivity and Na retention 143
Controls Group 1 Group2
NIDOM NIDDM
during insulin administration in Controls and Group 1 and 2
NIDDM patients.
During subcutaneous constant insulin infusion in the same 14
Controls, and in two cohorts of 17 Group 1 and 22 Group 2
NIDDM patients out of the overall 59 NIDDM population,
plasma glucose concentration was clamped at 4.5 mmol/liter
and 9.0 mmol/liter. The coefficient of variation of plasma
glucose concentration was similar in Controls and diabetics
(6%, 5% and 6%, respectively; Fig. 3). No glucose was found in
the urines during the euglycemic 240 minute period, whereas
the glucose loss was 1.6 0.5, 1.7 0.3 and 1.6 0.4 g1240 mm
in Controls and Group 1 and 2 NIDDM patients during the
hyperglycemic period, respectively. Plasma insulin concentra-
tion was similar in Controls and Group 1 and 2 NIDDM patients
during the euglycemic period (Fig. 3). No differences were
observed among NIDDM patients and Controls during the
hyperglycemic period with regard to plasma insulin levels,
which were, however, higher than during the euglycemic period
(Fig. 3). Hyperglycemia significantly lowered the sodium excre-
tion rate in comparison with the patterns observed during
euglycemia in Group 1 and 2 NIDDM patients and in Controls.
During the acute hyperglycemic clamp period the sodium
excretion rate was constantly lower in Group 2 than in Group 1
NIDDM patients and Controls (euglycemia and hyperglycemia
Controls vs. Group 1 vs. Group 2: 156 14 and 123 15 vs.
138 17 and 111 10; NS; vs. 101 8 and 74 9
jxmot . min' 1.73 m2, P < 0.01 vs. both; Fig. 3). No
significant differences were found between Group 1 NIDDM
patients and Controls.
The sodium excretion rate was inversely related to the
glucose filtered load (that is, to plasma glucose concentration)
in the range between 60 and 270 mg mm 1.73 m2, and was
directly proportional for higher GFL (Fig. 4). The estimated
model parameters are reported in Table 4. The slopes of Natr
versus GFL relationship both below and above GFL threshold
were not statistically different in the two groups, while baseline
natriuresis (natriuresis at the GFL average value in controls)
was lower (P = 0.0002) in Group 2 (Natr0, Table 4). This
resulted in a lower sodium excretion rate in Group 2 than Group
1 in spite of their having the same GFL. This difference was
statistically significant (P < 0.05) for GFL values up to 220
mg . min' . 1.73 m2 and was, in this range, at least 15
mmol . day' 1.73 m2.
At hyperglycemic plasma glucose concentrations (GFL
greater than an estimated value of 270mg. min' . 1.73 m2) the
rate of sodium excretion inverted its tendency, thus increasing
1.50
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Fig. 2. Mean SE rates of sodium excretion and renal clearance in
controls (•), Group 1 NIDDM (Li) and Group 2 NIDDM (0) at baseline(B) and during euglycemic-hyperinsulinemic (40 mU m2 . min')
clamp (I). *D < 0.05 Group 1 NIDDM and Group 2 NIDDM vs.
Controls; ** < 0.01 B vs. I. =
Cl,—
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Fig. 3. Mean SE plasma glucose and insulin concentrations and
rates of sodium excretion in controls (•), Group I NIDDM (Li) and
Group 2 (0) during euglycemic and hyperglycemic clamp with constant
subcutaneous insulin infusion, along with variable glucose administra-
tion rates to achieve and maintain either euglycemia or hyperglycemia.
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Fig. 4. Relationship between glucose filtered load and daily sodium
excretion rate in Group 1 NIDDM patients (0) and Group 2 NIDDM
patients (S) with less severely and markedly impaired peripheral insulin
sensitivity, Glucose filtered load was calculated by multiplying glomer-
ular filtration rate by the daily average plasma glucose concentration.
with increasing GFL values. The fitting curves were virtually
the same in the two groups.
In the fourteen Controls GFL values were closely clustered
in a narrow range (93 6 mg. min . 1.73 m2; mean SD;
range 70 to 107) due to the fact that their daily average plasma
glucose was closely clustered around 85 to 95 mg (88 3 mg/dl).
Controls had a daily average sodium excretion rate of 123 9
mmol . day. 1.73 m2.
Discussion
Previous studies on electrolyte reabsorption by renal tubules
in diabetic children provided evidence for a role of filtered
glucose in determining sodium retention [271. Filtered sodium
and tubular reabsorption of sodium were significantly higher in
diabetic children than in matched controls. The authors postu-
lated that this increase was due to enhanced, sodium-coupled
glucose reabsorption (co-transport) [281. In accord with these
findings are those of Hannedouche Ct al [11], who measured
lithium clearance in IDDM patients and confirmed higher
absolute and fractional reabsorption of sodium in the proximal
tubule of diabetic versus control subjects, as well as a decrease
in distal sodium delivery [11]. Recent reports in animals dem-
onstrate that increased sodium reabsorption appears to be
mediated by the brush border sodium-glucose co-transporter
[12], where the glucose/sodium stoichiometry of the transport is
found to be 1:2 [13]. In addition, these studies show that the
osmolality of the collected fluid fell to hypotonic levels and
resulted in an exaggerated transtubular osmotic gradient [12].
This gradient presumably acted as a passive driving force for
increased water reabsorption [13]. The increase in sodium
chloride transport in the proximal tubule with glucose transport
may be in part due to the solvent change. Sodium-glucose
transport generates a lumen negative potential which drives
chloride transport across the paracellular pathway. These ob-
servations, in summary, support the tenet that by increasing the
concentration of glucose in the proximal tubule, poor glycemic
control stimulates sodium and water absorption.
The present study further expands our knowledge on this
matter with respect to NIDDM. An inverse relationship was
found between the glucose filtered load and sodium excretion
rate in NIDDM patients within a clearly defined range of plasma
glucose. The filtered load from 60 to 270 mg. min1 . 1.73 m2
corresponded to glucose circulating patterns of 50 to 220 mg/dl.
Within this range plasma glucose concentrations seem to play a
major role in inhibiting natriuresis in NIDDM. This view is
further supported by the observation that moderate hypergly-
cemia, at 9 mmol/liter plasma glucose concentration, lowered
the sodium excretion rate in all NIDDM patients as well as in
controls, in comparison with the patterns found at euglycemic
levels. The sodium excretion rate, however, started again to
increase when plasma glucose levels exceeded the circulating
concentration of 220 to 250 mg/dl, suggesting that the capacity
of the kidney to reabsorb glucose and sodium by cotransport
mechanisms was to some extent saturated at these circulating
glucose concentrations. It can be postulated that osmotic diure-
sis due to severe hyperglycemia overcomes glucose-induced
sodium reabsorption above a threshold value of circulating
glucose levels between 250 to 300 mg/dl. On the contrary, when
plasma glucose was close to normal values, that is, at Natr0, the
extrapolated value of daily sodium excretion in NIDDM pa-
tients from Figure 4 at the GFL values of controls (93
mg min' . 1.73 m2 was equal to the daily sodium intake in
Group 1 NIDDM patients as in controls (Group 1 NIDDM vs.
Controls: 126 vs. 123 mmol . day' 1.73 m2). This finding
suggests that NIDDM patients with near-normal insulin sensi-
tivity achieve sodium balance when they are euglycemic.
However, this was not the case in Group 2 NIDDM patients
with severely impaired insulin sensitivity, who at Natr0 had an
extrapolated daily natriuresis of 104 mmol . day' 1.73 m2,
almost 15 mmol per day lower than their sodium intake during
the short term period of one week at a fixed sodium intake (Fig.
4, Table 4).
Although our results clearly demonstrate a role of hypergly-
cemia in the pathogenesis of sodium reabsorption in NIDDM,
the observation that patients with impaired action of insulin on
carbohydrate metabolism do have a more altered capacity to
handle sodium homeostasis than patients with normal insulin
sensitivity, even when blood glucose levels are similar, de-
serves emphasis. Namely, the inverse relation between sodium
180
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Table 4. Estimated parameters of the regression model used to
describe the relationship between daily sodium excretion rate and
glucose filtered load in Group 1 and Group 2 NIDDM patients
0
•.
20
.
Group 1
NIDDM
Group 2
NIDDM P value
k1
k2
Natr0
GFLat
r2
0.43
(12.1)a
1.54
(19.2)
126
(3.2)
275
(3.1)
0.784
0.40
(15.3)
1.57
(26.0)
104
(4.2)
269
(5.4)
0.626
0.66
0.95
0.0002
0.71
Percent coefficient of variation
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excretion rate and glucose filtered load for subjects on conven-
tional diabetic therapy and diet, was shifted to lower patterns in
Group 2 NIDDM patients with more pronounced hyperinsuline-
mia and insulin resistance, in comparison with diabetic patients
with an insulin action closer to that of normal subjects.
In summary, NIDDM patients with impaired insulin action
retain sodium at renal level, even when circulating glucose
concentrations and glucose filtered load are equal to those of
subjects with normal insulin sensitivity, at least during the
relatively short time period during the admission into the ward
where they are put at a fixed 125 mmol day . 1.73 m2
sodium intake.
These observations suggest that impaired insulin sensitivity,
besides glucose-induced sodium retention, contributes to curb
natriuresis in NIDDM. The question arises on the nature of the
pathogenetic link between insulin resistance and sodium reten-
tion. It seems plausible to suggest that hyperinsulinemia, sec-
ondary to the presence of more severe insulin resistance,
further deteriorates glucose-induced sodium retention in
NIDDM.
Insulin has been shown to be able to stimulate sodium
reabsorption in the proximal [28, 29] or distal [6, 10] renal
tubule after acute [6, 10] or chronic [29] administration. The
present study, in keeping with that of SkØtt et a! [10], shows
that the sodium retaining action of insulin is preserved in
NIDDM patients who have extrahepatic insulin resistance, with
respect to carbohydrate metabolism. Thus, one can postulate
that NIDDM patients with more impaired insulin action have
more severe sodium retention, as they exhibit marked hyperin-
sulinemia. However, this latter view is not supported by the
observation of the present study that Group 2 NIDDM patients
had a lower sodium excretion rate during subcutaneous insulin
administration, in spite of plasma glucose and insulin concen-
trations equal to those of Group 1 NIDDM patients and
Controls (Fig. 3).
Thus, alternatively, one can suggest the hypothesis that
insulin resistance itself, rather than hyperinsulinemia, reflects
an intrinsic abnormality of renal vascular bed in modulating
natriuresis. Recently we observed an association among insulin
resistance, abnormalities in Na/Li countertransport activity
in red blood cells, sodium retention and altered vascular func-
tion at renal and muscle levels in patients with essential
hypertension [30] and in hypertensive insulin-dependent diabet-
ics [31]. These observations are consistent with the view of
Shoback et a! [32] suggesting that a cohort of patients called
"non-modulators" have an impaired capacity to modulate renal
blood flow to accommodate changes in sodium intake, as well
as high red blood cell Na/Li countertransport activity, most
likely on a genetically partially inherited basis [33]. We suggest
that the present study describes insulin resistance as a further
clinical feature of this cohort of patients who can be identified
also among those with NIDDM. Eventually it can be postulated
that more severe hyperglycemia, secondary to markedly-im-
paired insulin sensitivity, plays an important role in curbing the
capacity of sodium excretion in NIDDM. One possibility is that
extracellular fluid volume might have been lower in Group 2
NIDDM patients if they had subtle, albeit not significant
differences in glycosuria, determining a hemodynamic predis-
position to sodium retention. However, hyperglycemia does
appear to be one of the major determinants of sodium retention,
but not the only one, as NIDDM patients with markedly
impaired insulin sensitivity have lower natriuresis than NIDDM
patients with less severely altered patterns of insulin action
despite equally elevated plasma glucose concentrations.
The novel finding of the present study is that impaired insulin
sensitivity, independently from circulating glucose and insulin
concentrations, is associated with sodium retention in NIDDM.
Insulin resistance, and not only hyperinsulinemia, appear to be
also linked with slightly elevated blood pressure levels and
albumin excretion rates, albeit still in the range of normality.
From a clinical point of view the results of the present study
highlight the contention that not only strict glycemic control,
but also improvement of insulin sensitivity must be pursued to
prevent sodium retention in NIDDM.
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